These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34916245)

  • 1. Comparison of
    Zeydan B; Schwarz CG; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
    J Nucl Med; 2022 Aug; 63(8):1239-1244. PubMed ID: 34916245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities.
    Goodheart AE; Tamburo E; Minhas D; Aizenstein HJ; McDade E; Snitz BE; Price JC; Mathis CA; Lopez OL; Klunk WE; Cohen AD
    Neuroimage Clin; 2015; 9():479-83. PubMed ID: 26594630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of [
    Lowe VJ; Lundt E; Knopman D; Senjem ML; Gunter JL; Schwarz CG; Kemp BJ; Jack CR; Petersen RC
    Neuroimage Clin; 2017; 16():295-302. PubMed ID: 28856092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White Matter Reference Region in PET Studies of
    Lowe VJ; Lundt ES; Senjem ML; Schwarz CG; Min HK; Przybelski SA; Kantarci K; Knopman D; Petersen RC; Jack CR
    J Nucl Med; 2018 Oct; 59(10):1583-1589. PubMed ID: 29674420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced [
    Moscoso A; Grothe MJ; Schöll M;
    Eur J Nucl Med Mol Imaging; 2021 Jul; 48(7):2283-2294. PubMed ID: 33475761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
    Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data.
    Lundqvist R; Lilja J; Thomas BA; Lötjönen J; Villemagne VL; Rowe CC; Thurfjell L
    J Nucl Med; 2013 Aug; 54(8):1472-8. PubMed ID: 23740104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.
    Rowe CC; Pejoska S; Mulligan RS; Jones G; Chan JG; Svensson S; Cselényi Z; Masters CL; Villemagne VL
    J Nucl Med; 2013 Jun; 54(6):880-6. PubMed ID: 23575995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of white matter PiB uptake as a marker of white matter integrity.
    Zeydan B; Schwarz CG; Lowe VJ; Reid RI; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Gunter JL; Min HK; Vemuri P; Knopman DS; Petersen RC; Jack CR; Kantarci OH; Kantarci K
    Ann Clin Transl Neurol; 2019 Apr; 6(4):678-688. PubMed ID: 31019992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.
    Leinonen V; Rinne JO; Virtanen KA; Eskola O; Rummukainen J; Huttunen J; von Und Zu Fraunberg M; Nerg O; Koivisto AM; Rinne J; Jääskeläinen JE; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajärvi M; Heurling K; Grachev ID
    Eur J Neurol; 2013 Jul; 20(7):1043-52. PubMed ID: 23398333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of
    Hashimoto T; Yokota C; Koshino K; Temma T; Yamazaki M; Iguchi S; Shimomura R; Uehara T; Funatsu N; Hino T; Minematsu K; Iida H; Toyoda K
    Ann Nucl Med; 2017 Apr; 31(3):227-234. PubMed ID: 28220365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual assessments of 11 C-Pittsburgh compound-B PET vs. 18 F-flutemetamol PET across the age spectrum.
    Zeydan B; Johnson DR; Schwarz CG; Przybelski SA; Lesnick TG; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
    Nucl Med Commun; 2024 Dec; 45(12):1047-1054. PubMed ID: 39267525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.
    Auvity S; Tonietto M; Caillé F; Bodini B; Bottlaender M; Tournier N; Kuhnast B; Stankoff B
    Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):490-501. PubMed ID: 31686177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
    Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Zeydan B; Lowe VJ; Schwarz CG; Przybelski SA; Tosakulwong N; Zuk SM; Senjem ML; Gunter JL; Roberts RO; Mielke MM; Benarroch EE; Rodriguez M; Machulda MM; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Kantarci K; Kantarci OH
    Mult Scler; 2018 May; 24(6):739-749. PubMed ID: 28474977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.
    Pietroboni AM; Carandini T; Colombi A; Mercurio M; Ghezzi L; Giulietti G; Scarioni M; Arighi A; Fenoglio C; De Riz MA; Fumagalli GG; Basilico P; Serpente M; Bozzali M; Scarpini E; Galimberti D; Marotta G
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):280-287. PubMed ID: 30343433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
    Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; Andersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ
    Ann Neurol; 2010 Sep; 68(3):319-29. PubMed ID: 20687209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.